The FDA issued a warning about the use of compounded ketamine products, including oral formulations, for treating psychiatric disorders, due to a recent increased interest.
EQS-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Personnel Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Office 31.10.2024 / 16:03 CET/CEST
Kymera’s KT-253 is being explored in a variety of liquid and solid tumours. Source: Shutterstock / Juan Gaertner. Clinical-stage biopharma Kymera Therapeutics has announced that